**2021 ICD-O-3.2 UPDATE**

**TABLES 1-5**

**Table 1: New behavior codes (Reportable neoplasms)**

WHO has changed behavior codes for the following terms which result in previously non-reportable neoplasms becoming reportable for cases diagnosed 1/1/2021 forward. DO NOT report cases diagnosed prior to 1/1/2021.

|  |  |  |  |
| --- | --- | --- | --- |
| **Action** | **ICD-O****Code** | **Term/Site** | **Comments** |
| New behavior | 8077/2 | Squamous intraepithelial neoplasia, grade II | Change from /0 **Excludes cervix**Refer to standard setter and/or state guidelines for further reportability guidelines  |
| New behavior | 8150/3 | Pancreatic endocrine tumor, NOS (C25.4)Islet cell adenoma (C25.4)Islet cell adenomatosis (C25.4)Nesidioblastoma (C25.4)Islet cell tumor, NOS (C25.4) | Change from /1 Change from /0Change from /0Change from /0Change from /1 |
| New behavior | 8151/3 | Insulinoma, NOS (C25.4)Beta cell adenoma (C25.4) | Change from /0Change from /0 |
| New behavior | 8158/3 | ACTH-producing tumorEndocrine tumor, functioning, NOS | Change from /1  |
| New behavior code and term | 8380/2 | Endometrioid intraepithelial neoplasia (C54.1) |  |
| New behavior code | 8408/3 | Aggressive digital papillary adenoma (C44. \_) | Change from behavior /1 |
| New behavior/term | 8452/3 | Solid pseudopapillary neoplasm of pancreas | Change from /1  |
| New behavior code and term | 8620/3 | Granulosa cell tumor, adult type (C56.9) | Reportable for cases diagnosed 1/1/2021 forward |
| New behavior/term | 8690/3 | **Middle ear paraganglioma (C30.1, C755.5))**Glomus jugulare tumor, NOS (C75.5)Jugular paraganglioma C75.5)Jugulotympanic paraganglioma (C75.5) | Change from /1 |
| New behavior code | 8691/3 | **Aortic body tumor (C75.5)**Aortic body paraganglioma (75.5)Aorticopulmonary paraganglioma (C75.5) | Change form /1 |
| New behavior/term | 8692/3 | **Carotid body paraganglioma (C75.4)**Carotid body tumor (75.4) | Change from /1  |
| New behavior code | 8693/3 | **Extra-adrenal paraganglioma, NOS**Nonchromaffin paraganglioma, NOSChemodectoma Composite paragangliomaLaryngeal paragangliomaVagal paraganglioma | Change from /1 |
| New behavior | 8700/3 | **Pheochromocytoma, NOS (74.1)**Adrenal medullary paraganglioma (74.1)Chromaffin paraganglioma (C74.1)Chromaffin tumorChromaffinomaComposite pheochromocytoma (C74.1)Pheochromoblastoma C74.1) | Change from /0 |
| New behavior code | 8936/3 | Gastrointestinal autonomic nerve tumorGANTGastrointestinal pacemaker cell tumor | Change from /1  |
| New behavior/term | 9505/0 | Multinodular and vascolating neuronal tumor (MVNT) (C71.2) |  |
| New behavior/term | 9766/3 | Lymphomatoid granulomatosis, grade 3 |  |

**Table 2: New behavior codes (Non-reportable neoplasms)**

WHO has changed behavior codes for the following terms which result in reportable neoplasms becoming non-reportable beginning with cases diagnosed 1/1/2021. Continue reporting these cases when diagnosed prior to 1/1/2021.

|  |  |  |  |
| --- | --- | --- | --- |
| **Action** | **ICD-O****Code** | **Term/Site** | **Comments** |
| New behavior | 8832/1 | Dermatofibrosarcoma protuberans, NOS (C44. \_)Dermatofibrosarcoma, NOS (C44. \_) | Change from /3  |
| New behavior | 8833/1 | Pigmented dermatofibrosarcoma protuberans (C44. \_)Bednar tumor (C44. \_) | Change from /3  |
| New behavior code (***for specific sites only)*** | 9080/1 | Immature teratoma of the lung (C34. \_)Immature teratoma of thymus (C37.9)Immature teratoma of thyroid (C73.9) | Change from behavior /3 for the histology/site combination will make these terms non-reportable |
| New behavior code | 9709/1 | Primary cutaneous CD4-positive small/medium T-cell lymphoma (C44. \_) | Change from /3 |
| New behavior code | 9718/1 | Primary cutaneous CD30+ T cell lymphoproliferative disorder (C44. \_)Lymphoid papulosis (C44. \_) | Change for /3 |
| New behavior/term | 9725/1 | Hydroa vacciniforme-like lymphoproliferative disorder | Change from /3.  |
| New behavior code | 9751/1 | Langerhans cell histiocytosis, NOSLangerhans cell histiocytosis, monostoticLangerhans cell histiocytosis, polystotic | Change from /3 |
| New behavior | 9971/1 | Polymorphic Post Transplant Lymphoproliferative Disorder (PTLD) | Change from /3  |
| New behavior & term | 8335/1 | Follicular tumor of uncertain malignant potential (C73.0) Preferred termFollicular carcinoma, encapsulated (C73.9) | Change from /3 |

**Table 3: Deleted ICD-O codes in ICD-O-3.2**

Per ICD-O-3.2, several ICD-O codes have been removed and the histologies moved to other codes. The comment column provides coding instructions for cases diagnosed prior to 1/1/2021 and 1/1/2021 forward. This table lists only ***reportable*** neoplasms.

|  |  |  |  |
| --- | --- | --- | --- |
| **ICD-O-3/3.1****Code/behavior** | **Term(s)** | **ICD-O-3.2 code****(1/1/2021)** | **Comments** |
| 8471/3 | Papillary mucinous cystadenocarcinoma (C56.9)Papillary pseudomucinous cystadenocarcinoma (C56.9) | 8470/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 8471/3Cases diagnosed 1/1/2021 forward use code 8470/3 |
| 9150/3 | Hemangiopericytoma, malignant | 8815/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9150/3Cases diagnosed 1/1/2021 forward use code 8815/3 |
| 9260/3 | Ewing sarcoma | 9364/3 | 1/1/2021 forward Ewing sarcoma is the preferred term for 9364/3 and is no longer coded to 9260/3. Cases DX’d prior to 1/1/2021 should be coded to 9260/3 |
| 9670/3 | Malignant lymphoma, small B lymphocytic, NOS *(see also M-**9823/3)*Malignant lymphoma, lymphocytic, diffuse, NOSMalignant lymphoma, lymphocytic, NOSMalignant lymphoma, lymphocytic, well differentiated, diffuseMalignant lymphoma, small cell diffuseMalignant lymphoma, small cell, NOSMalignant lymphoma, small lymphocytic, diffuseMalignant lymphoma, small lymphocytic, NOS | 9823/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3 |
| 9728/3 | Precursor B-cell lymphoblastic lymphoma *(see also M-**9836/3)* | 9811/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9728/3Cases diagnosed 1/1/2021 forward use code 9811/3 |
| 9729/3 | Precursor T-cell lymphoblastic lymphoma *(see also M-**9837/3)* | 9837/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9729/3Cases diagnosed 1/1/2021 forward use code 9837/3 |
| 9826/3 | Burkitt cell leukemia *(see also M-9687/3)*Acute leukemia, Burkitt type [obs]Acute lymphoblastic leukemia, mature B-cell typeB-ALL [obs]FAB L3 [obs] | 9687/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9826/3Cases diagnosed 1/1/2021 forward use code 9687/3 |
| 9836/3 | Precursor B-cell lymphoblastic leukemia *(see also M-9728/3)*c-ALLCommon ALLCommon precursor B ALLPre-B ALLPre-pre-B ALLPro-B ALL | 9811/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3 |
| 9991/3 | Refractory neutropenia | 9980/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9991/3Cases diagnosed 1/1/2021 forward use code 9980/3 |
| 9992/3 | Refractory thrombocytopenia | 9980/3 | Cases diagnosed ***prior*** to 1/1/2021 use code 9992/3Cases diagnosed 1/1/2021 forward use code 9980/3 |

**Table 4: Changes in reportable terminology**

**(\*)** WHO has revised preferred terminology for these neoplasms and no longer requires “malignant” to be used in the term in order to code behavior of /3

|  |  |  |  |
| --- | --- | --- | --- |
| **Action** | **ICD-O****Code** | **Term/Site** | **Comments** |
| New term | 8151/3 | Insulinoma | **(\*)** |
| New term | 8152/3 | Glucagonoma | **(\*)** |
| New term | 8153/3 | Gastrinoma | **(\*)** |
| New term | 8155/3 | VIPoma | **(\*)** |
| New term | 8156/3 | Somatostatinoma | **(\*)** |
| New term | 8580/3 | Thymoma, NOS (C37.9)Metaplastic thymoma **(C37.9)**Sclerosing thymoma (C34. \_)Intrapulmonary thymoma C34. \_) | **(\*)** |
| New term | 8581/3 | Type A thymoma including atypical variant **(C37.9)** | **(\*)** |
| New term | 8582/3 | Type AB thymoma **(C37.9)** | **(\*)** |
| New term | 8583/3 | Type B1 thymoma **(C37.9)** | **(\*)** |
| New term | 8584/3 | Type B2 thymoma **(C37.9)** | **(\*)** |
| New term | 8585/3 | Type B3 thymoma **(C37.9)**Thymoma, atypical **(C37.9)**Thymoma, epithelial **(C37.9)** | **(\*)** |
| New Pref term | 8693/3 | Paraganglioma | **(\*)** |
| New term | 8700/3 | Pheochromocytoma  | **(\*)** |

**(\*) prior to 1/1/2021, these histologies were reportable only when the pathologist included “malignant” in the diagnosis term. Example: thymoma, malignant or malignant thymoma. WHO as dropped malignant from the reportable term. All of the neoplasms listed are reportable as /3 unless stated to be benign**

**Table 5: New Terms and ICD-O codes**

|  |  |  |  |
| --- | --- | --- | --- |
| **Action** | **ICD-O****Code** | **Term/site** | **Comment** |
| New code/termSynonym | 8273/3 | Pituitary blastomaEmbryoma |  |
| New code/term | 9749/3 | Erdhiem-Chester Disease |  |
| New code/term | 9766/3 | Lymphomatoid granulomatosis, grade 3 |  |
| New code/term | 9819/3 | B-lymphocytic leukemia/lymphoma, BCR-ABL1-like |  |
| New code/term | 9877/3 | Acute myeloid leukemia with mutated NPM1 |  |
| New code/term | 9878/3 | Acute myeloid leukemia with biallelic mutations of CEBPA |  |
| New code/term | 9879/3 | Acute myeloid leukemia with mutated RUNX1 |  |
| New code/term | 9912/3 | Acute myeloid leukemia with BCR-ABL1 |  |
| New code/term | 9968/3 | Myeloid/lymphoid neoplasms with PCM1-JAK2 |  |
| New code/term | 9993/3 | Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia |  |
| New code/term | 9715/3 | Anaplastic large cell lymphoma ALK-negative Breast implant-associated anaplastic large cell lymphoma |  |
| New code/term | 8349/1 | Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) C73.9)Non-invasive FTP (C73.9) | **This term was previously coded to 8343/2. The new code and behavior will make this non-reportable** |